---
document_datetime: 2025-12-02 05:26:09
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/teriflunomide-accord.html
document_name: teriflunomide-accord.html
version: success
processing_time: 0.1303751
conversion_datetime: 2025-12-23 20:32:07.231358
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Teriflunomide Accord

[RSS](/en/individual-human-medicine.xml/67623)

##### Authorised

This medicine is authorised for use in the European Union

teriflunomide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Teriflunomide Accord](#news-on)
- [More information on Teriflunomide Accord](#more-information-on-teriflunomide-accord-1631)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Teriflunomide Accord is a medicine used to treat patients from the age of 10 years with multiple sclerosis (MS), a disease in which inflammation attacks the protective covering (sheath) around nerves and damages the nerves themselves.

Teriflunomide Accord is used in the type of MS known as relapsing-remitting MS, when the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).

Teriflunomide Accord is a 'generic medicine'. This means that Teriflunomide Accord contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU called Aubagio. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf) .

Teriflunomide Accord contains the active substance teriflunomide.

Expand section

Collapse section

## How is Teriflunomide Accord used?

Teriflunomide Accord can only be obtained with a prescription and treatment should be started and supervised by a doctor who has experience in the management of MS.

Teriflunomide Accord is available as tablets. The recommended dose for adults is 14 mg once a day. The dose for children depends on their body weight. For more information about using Teriflunomide Accord, see the package leaflet or contact your doctor or pharmacist.

## How does Teriflunomide Accord work?

In multiple sclerosis , the immune system (the body's natural defences) incorrectly attacks the protective sheath around the nerves and the nerves themselves in the brain and spinal cord. The active substance in Teriflunomide Accord, teriflunomide, blocks an enzyme called 'dihydroorotate dehydrogenase' which is necessary for cells to multiply. The exact way teriflunomide works in MS is not known but it is thought to reduce the number of T-lymphocytes which form part of the immune system and are involved in the inflammation process. With fewer T-lymphocytes, there is less inflammation, helping to control the symptoms of MS.

## How has Teriflunomide Accord been studied?

Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Aubagio, and do not need to be repeated for Teriflunomide Accord.

As for every medicine, the company provided studies on the quality of Teriflunomide Accord. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Teriflunomide Accord?

Because Teriflunomide Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Teriflunomide Accord authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Teriflunomide Accord has been shown to have comparable quality and to be bioequivalent to Aubagio. Therefore, the Agency's view was that, as for Aubagio, the benefits of Teriflunomide Accord outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Teriflunomide Accord?

The company that markets Teriflunomide Accord must ensure that all healthcare professionals who are expected to prescribe this medicine receive educational material containing important safety information, including the tests and monitoring that should be carried out in patients before and after starting treatment. The company must also provide patient education cards with key safety information for patients.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Teriflunomide Accord have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Teriflunomide Accord are continuously monitored. Suspected side effects reported with Teriflunomide Accord are carefully evaluated and any necessary action taken to protect patients.

## Other information about Teriflunomide Accord

Teriflunomide Accord received a marketing authorisation valid throughout the EU on 09 November 2022.

Teriflunomide Accord : EPAR - Medicine Overview

Reference Number: EMA/CHMP/857461/2022

English (EN) (144.61 KB - PDF)

**First published:** 14/11/2022

[View](/en/documents/overview/teriflunomide-accord-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-917)

български (BG) (157.52 KB - PDF)

**First published:**

14/11/2022

[View](/bg/documents/overview/teriflunomide-accord-epar-medicine-overview_bg.pdf)

español (ES) (135.48 KB - PDF)

**First published:**

14/11/2022

[View](/es/documents/overview/teriflunomide-accord-epar-medicine-overview_es.pdf)

čeština (CS) (154.71 KB - PDF)

**First published:**

14/11/2022

[View](/cs/documents/overview/teriflunomide-accord-epar-medicine-overview_cs.pdf)

dansk (DA) (134.55 KB - PDF)

**First published:**

14/11/2022

[View](/da/documents/overview/teriflunomide-accord-epar-medicine-overview_da.pdf)

Deutsch (DE) (138.79 KB - PDF)

**First published:**

14/11/2022

[View](/de/documents/overview/teriflunomide-accord-epar-medicine-overview_de.pdf)

eesti keel (ET) (122.98 KB - PDF)

**First published:**

14/11/2022

[View](/et/documents/overview/teriflunomide-accord-epar-medicine-overview_et.pdf)

ελληνικά (EL) (157.64 KB - PDF)

**First published:**

14/11/2022

[View](/el/documents/overview/teriflunomide-accord-epar-medicine-overview_el.pdf)

français (FR) (135.86 KB - PDF)

**First published:**

14/11/2022

[View](/fr/documents/overview/teriflunomide-accord-epar-medicine-overview_fr.pdf)

hrvatski (HR) (153.75 KB - PDF)

**First published:**

14/11/2022

[View](/hr/documents/overview/teriflunomide-accord-epar-medicine-overview_hr.pdf)

italiano (IT) (133.75 KB - PDF)

**First published:**

14/11/2022

[View](/it/documents/overview/teriflunomide-accord-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (172.93 KB - PDF)

**First published:**

14/11/2022

[View](/lv/documents/overview/teriflunomide-accord-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (154.98 KB - PDF)

**First published:**

14/11/2022

[View](/lt/documents/overview/teriflunomide-accord-epar-medicine-overview_lt.pdf)

magyar (HU) (155.83 KB - PDF)

**First published:**

14/11/2022

[View](/hu/documents/overview/teriflunomide-accord-epar-medicine-overview_hu.pdf)

Malti (MT) (158.4 KB - PDF)

**First published:**

14/11/2022

[View](/mt/documents/overview/teriflunomide-accord-epar-medicine-overview_mt.pdf)

Nederlands (NL) (135.04 KB - PDF)

**First published:**

14/11/2022

[View](/nl/documents/overview/teriflunomide-accord-epar-medicine-overview_nl.pdf)

polski (PL) (158.95 KB - PDF)

**First published:**

14/11/2022

[View](/pl/documents/overview/teriflunomide-accord-epar-medicine-overview_pl.pdf)

português (PT) (136.01 KB - PDF)

**First published:**

14/11/2022

[View](/pt/documents/overview/teriflunomide-accord-epar-medicine-overview_pt.pdf)

română (RO) (152.57 KB - PDF)

**First published:**

14/11/2022

[View](/ro/documents/overview/teriflunomide-accord-epar-medicine-overview_ro.pdf)

slovenčina (SK) (155.7 KB - PDF)

**First published:**

14/11/2022

[View](/sk/documents/overview/teriflunomide-accord-epar-medicine-overview_sk.pdf)

slovenščina (SL) (181.5 KB - PDF)

**First published:**

14/11/2022

[View](/sl/documents/overview/teriflunomide-accord-epar-medicine-overview_sl.pdf)

Suomi (FI) (132.98 KB - PDF)

**First published:**

14/11/2022

[View](/fi/documents/overview/teriflunomide-accord-epar-medicine-overview_fi.pdf)

svenska (SV) (133.51 KB - PDF)

**First published:**

14/11/2022

[View](/sv/documents/overview/teriflunomide-accord-epar-medicine-overview_sv.pdf)

Teriflunomide Accord : EPAR - Risk management plan

English (EN) (1.77 MB - PDF)

**First published:** 14/11/2022

**Last updated:** 02/05/2024

[View](/en/documents/rmp/teriflunomide-accord-epar-risk-management-plan_en.pdf)

## Product information

Teriflunomide Accord : EPAR - Product Information

English (EN) (603.6 KB - PDF)

**First published:** 14/11/2022

**Last updated:** 29/07/2024

[View](/en/documents/product-information/teriflunomide-accord-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-728)

български (BG) (914.14 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/bg/documents/product-information/teriflunomide-accord-epar-product-information_bg.pdf)

español (ES) (636.3 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/es/documents/product-information/teriflunomide-accord-epar-product-information_es.pdf)

čeština (CS) (819.25 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/cs/documents/product-information/teriflunomide-accord-epar-product-information_cs.pdf)

dansk (DA) (847.05 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/da/documents/product-information/teriflunomide-accord-epar-product-information_da.pdf)

Deutsch (DE) (569.88 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/de/documents/product-information/teriflunomide-accord-epar-product-information_de.pdf)

eesti keel (ET) (640.73 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/et/documents/product-information/teriflunomide-accord-epar-product-information_et.pdf)

ελληνικά (EL) (1021.95 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/el/documents/product-information/teriflunomide-accord-epar-product-information_el.pdf)

français (FR) (864.48 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/fr/documents/product-information/teriflunomide-accord-epar-product-information_fr.pdf)

hrvatski (HR) (684.88 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/hr/documents/product-information/teriflunomide-accord-epar-product-information_hr.pdf)

íslenska (IS) (627.78 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/is/documents/product-information/teriflunomide-accord-epar-product-information_is.pdf)

italiano (IT) (858.09 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/it/documents/product-information/teriflunomide-accord-epar-product-information_it.pdf)

latviešu valoda (LV) (1.06 MB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/lv/documents/product-information/teriflunomide-accord-epar-product-information_lv.pdf)

lietuvių kalba (LT) (698.9 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/lt/documents/product-information/teriflunomide-accord-epar-product-information_lt.pdf)

magyar (HU) (827.5 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/hu/documents/product-information/teriflunomide-accord-epar-product-information_hu.pdf)

Malti (MT) (791.17 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/mt/documents/product-information/teriflunomide-accord-epar-product-information_mt.pdf)

Nederlands (NL) (775.17 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/nl/documents/product-information/teriflunomide-accord-epar-product-information_nl.pdf)

norsk (NO) (651 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/no/documents/product-information/teriflunomide-accord-epar-product-information_no.pdf)

polski (PL) (728.56 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/pl/documents/product-information/teriflunomide-accord-epar-product-information_pl.pdf)

português (PT) (812.13 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/pt/documents/product-information/teriflunomide-accord-epar-product-information_pt.pdf)

română (RO) (935.92 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/ro/documents/product-information/teriflunomide-accord-epar-product-information_ro.pdf)

slovenčina (SK) (766.41 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/sk/documents/product-information/teriflunomide-accord-epar-product-information_sk.pdf)

slovenščina (SL) (706.26 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/sl/documents/product-information/teriflunomide-accord-epar-product-information_sl.pdf)

Suomi (FI) (676.8 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/fi/documents/product-information/teriflunomide-accord-epar-product-information_fi.pdf)

svenska (SV) (621.44 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/07/2024

[View](/sv/documents/product-information/teriflunomide-accord-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** PSUSA/00010135/202309 26/07/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Teriflunomide Accord : EPAR - All authorised presentations

English (EN) (85.5 KB - PDF)

**First published:** 14/11/2022

**Last updated:** 25/04/2024

[View](/en/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-803)

български (BG) (93.76 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/bg/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_bg.pdf)

español (ES) (86.13 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/es/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_es.pdf)

čeština (CS) (89.89 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/cs/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (86.81 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/da/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (87.82 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/de/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (86.17 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/et/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (92.73 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/el/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_el.pdf)

français (FR) (87.63 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/fr/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (88.89 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/hr/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (88.15 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/is/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_is.pdf)

italiano (IT) (85.6 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/it/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (91.22 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/lv/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (91.63 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/lt/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (92.23 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/hu/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (91.26 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/mt/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (258.19 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/nl/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (87.25 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/no/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_no.pdf)

polski (PL) (88.98 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/pl/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_pl.pdf)

português (PT) (86.9 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/pt/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_pt.pdf)

română (RO) (89.13 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/ro/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (91.46 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/sk/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (89.75 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/sl/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (86.28 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/fi/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (85.96 KB - PDF)

**First published:**

14/11/2022

**Last updated:**

25/04/2024

[View](/sv/documents/all-authorised-presentations/teriflunomide-accord-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Teriflunomide Accord Active substance teriflunomide International non-proprietary name (INN) or common name teriflunomide Therapeutic area (MeSH) Multiple Sclerosis, Relapsing-Remitting Anatomical therapeutic chemical (ATC) code L04AA31

### Pharmacotherapeutic group

- Immunosuppressants
- Selective immunosuppressants

### Therapeutic indication

Teriflunomide Accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established).

## Authorisation details

EMA product number EMEA/H/C/005960

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 15/09/2022 Marketing authorisation issued 09/11/2022 Revision 3

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Teriflunomide Accord : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.79 KB - PDF)

**First published:** 17/04/2024

**Last updated:** 29/07/2024

[View](/en/documents/procedural-steps-after/teriflunomide-accord-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Teriflunomide Accord-H-C-PSUSA-00010135-202309 : Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/240603/2024

English (EN) (141.58 KB - PDF)

**First published:** 29/07/2024

[View](/en/documents/scientific-conclusion/teriflunomide-accord-h-c-psusa-00010135-202309-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Teriflunomide Accord-H-C-005960-X-0002 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/CHMP/108990/2024

English (EN) (904.3 KB - PDF)

**First published:** 25/04/2024

[View](/en/documents/variation-report/teriflunomide-accord-h-c-005960-x-0002-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Teriflunomide Accord : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/805980/2022

English (EN) (810.27 KB - PDF)

**First published:** 14/11/2022

[View](/en/documents/assessment-report/teriflunomide-accord-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Teriflunomide Accord

Adopted

Reference Number: EMA/CHMP/748820/2022

English (EN) (127.97 KB - PDF)

**First published:** 16/09/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-teriflunomide-accord_en.pdf)

#### News on Teriflunomide Accord

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 September 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-september-2022) 16/09/2022

#### More information on Teriflunomide Accord

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

**This page was last updated on** 29/07/2024

## Share this page

[Back to top](#main-content)